Organization

9 Months Ended

Sep. 30, 2012

Accounting Policies [Abstract]

Nature of Operations [Text Block]

1.   Organization

Synthetic Biologics, Inc. (the “Company” or “Synthetic Biologics”), formerly Adeona Pharmaceuticals, Inc., is a biotechnology company focused on the development of synthetic biologics and innovative medicines for serious infections and diseases. The Company is developing a series of monoclonal antibodies (mAbs) for the treatment of certain infectious diseases and a synthetic DNA-based therapy for the treatment of pulmonary arterial hypertension (PAH). In addition, Synthetic Biologics is developing a product candidate to treat relapsing-remitting multiple sclerosis (MS) and cognitive dysfunction in MS; designing a clinical development pathway for the treatment of amyotrophic lateral sclerosis (ALS); and, has partnered the development of a treatment for fibromyalgia. The Company is also evaluating additional in-licensing opportunities.

Therapeutic Area	Product Candidate	Status
Acinetobacter infection	SYN-001	Discovery; Collaboration with Intrexon
	(monoclonal antibody)
Infectious disease*	SYN-002	Discovery; Collaboration with Intrexon
	(monoclonal antibody)
Infectious disease*	SYN-003	Discovery; Collaboration with Intrexon
	(monoclonal antibody)
PAH	SYN-PAH	Preclinical; Collaboration with Intrexon
	(synthetic DNA-based therapy)
Relapsing-remitting MS	Trimesta (oral estriol)	Patients fully enrolled in Phase II clinical trial; dosing and monitoring underway
Cognitive dysfunction in MS	Trimesta (oral estriol)	Patient enrollment underway in Phase II clinical trial
ALS	AEN-100	Clinical trial design ongoing
	(gastroretentive zinc acetate)
Fibromyalgia	Effirma	Partnered with Meda AB
	(oral flupirtine)

 *Infectious disease targets to be disclosed in the future.